You have successfully logged out.

search
menu
close
What are you looking for?
close close

Drug Coated Balloon

The Class 1A ESC recommendation for DCB in ISR

Based on studies which were mainly performed with SeQuent® Please/NEO coating technology (PACCOCATH®)

European Society of Cardiology

The European Society of Cardiology (ESC) recommends the usage of drug coated balloons (DCB) to treat coronary in-stent restenosis (within BMS or DES) with its highest possible evidence class: IA. [1]

 

In its recommendation the ESC considers studies which were performed in its majority with the SeQuent® Please product family. As there are different DCB technologies in the market, the ESC indicated that a class effect for all DCBs cannot be assumed. [1]

Therefore, it might be concluded that the ESC recommendation is based on the SeQuent® Please coating technology.

 

Extract from studies used in the ESC recommendations [1] referring to the coating (PACCOCATH®-Technology) of SeQuent® Please product family for the usage in in-stent restenosis (ISR) treatment:

PACCOCATH ISR I [2] and II [3]

  • Randomized Controlled Trial in a total of 108 patients shows
  • Superiority for DCB vs. POBA in BMS-ISR after 6 months [2]  and 5 years [3]
  • In-Segment LLL @ 6-month: 0.11 ± 0.44 mm [2]
  • Binary Restenosis Rate In-Segment @ 6-month: 3 / 54 (6%) [2]
  • MACE @ 5-year: 27.8% [3]
  • TLR @ 5-year: 9.3% [3] 

PEPCAD II [4]

  • Randomized Controlled Trial in a total of 130 patients shows
  • As least as efficient than DES usage in BMS-ISR [4]
  • In-Segment LLL @ 6-month 0.17 ± 0.42 mm [4]
  • Binary Restenosis Rate In-Segment: 4 / 57 (7%) [4]
  • MACE @ 12-month: 9% [4]
  • TLR @ 12-month: 6% [4]

PEPCAD-DES [5]

  • Randomized Controlled Trial in a total of 110 patients demonstrates
  • Superiority for DCB vs. POBA in DES-ISR
  • In-Segment LLL @ 6-month 0.43 ± 0.61 mm [5]
  • Binary Restenosis Rate In-Segment: 17.2% [5]
  • Significant lower MACE for DCB [5]

Kurashiki [6]

  • Randomized Controlled Trial in a total of 74 patients shows
  • Superiority for DCB vs. POBA in DES-ISR [6]
  • In-Segment LLL @ 6-month 0.18 ± 0.45 mm [6]
  • Binary Restenosis Rate In-Segment: 2 / 23 (8.7%) [6]
  • TLR @ 6-month: 4.3% [6]

Follow-up data after treatment with SeQuent® Please BMS-ISR and DES-ISR are available from 6 months [3], [4], [5], [6] up to 5 years. [3]

Image is temporarily not available.

Coronary Drug Coated Balloon

THINK ABOUT…

Clinical evidence on drug coated balloons and learn more about the “Best investigated DCB”.
Find out more

Get in touch with our Coronary Drug Coated Balloon​ experts

Coronary Drug Coated Balloon​​ contact form

[1] Neumann FJ et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. 

[2] Scheller B et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113–2124.

[3] Scheller B et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5:323-30.

[4] Unverdorben et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. EuroIntervention. 2015;11:926-934.

[5] Rittger H et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis. JACC. 2012;59:1377-82.

[6] Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:149-54.

Stay connected with My B. Braun

We want to offer individual services via our business customer portal “My B. Braun”.  Please help us to adapt our portal and services to your needs. 

person_outline Attend survey now!